Pharma

Dec 1 2017

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #pharma #world

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Aug 8 2017

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #generic #pharmaceuticals

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Jul 4 2017

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #gland #pharma

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

May 15 2017

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #acceleron #pharma

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Mar 18 2017

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #msd #pharma

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Feb 12 2017

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #pharma #brands

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Nov 21 2016

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #medical #sales #jobs

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Nov 12 2016

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #pharma #conference

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Nov 3 2016

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #marketing #pharmaceuticals

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …

Sep 27 2016

Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …